A Repeat Achievement in Biotech Innovation
Paradigm Therapeutics Inc. has once again solidified its position at the forefront of medical innovation. For the second consecutive year, the company has been nominated for the highly esteemed Prix Galien USA 2026. This recognition highlights the company’s commitment to pushing the boundaries of dermatological science.
The Innovation: SD-101 (Zorblesia)
The nomination celebrates the development of SD-101 (Zorblesia), an advanced topical treatment designed to address conditions across the entire surface of the skin. This therapeutic candidate has caught the attention of the industry for its potential to provide comprehensive relief and treatment in a category that demands high-precision solutions.
Why the Prix Galien Matters
Known as the “Nobel Prize of biopharmaceutical research,” the Prix Galien recognizes excellence in scientific innovation that improves the human condition. Being nominated in the “Best Start-up” category for two years running underscores Paradigm Therapeutics’ consistency in delivering meaningful clinical breakthroughs.
Key Highlights of the Nomination:
- Recognition of Excellence: Nominated for the “Best Start-up” category at Prix Galien USA 2026.
- Consecutive Success: Marks the second year in a row that Paradigm Therapeutics has received this prestigious acknowledgment.
- Clinical Focus: The focus remains on SD-101 (Zorblesia), a specialized topical solution for full-surface skin treatment.
- Industry Impact: Reinforces the company’s growing influence in the dermatology and biotechnology sectors.
As Paradigm Therapeutics continues its clinical development, the scientific community eagerly anticipates the future impact of Zorblesia on patient outcomes worldwide.
Source: Read More